Analyst Ratings For Cidara Therapeutics (NASDAQ:CDTX)
Today, Cidara Therapeutics (NASDAQ:CDTX) stock was downgraded by WBB Securities from Strong-Buy to .
There are 8 buy ratings, 2 strong buy ratings on the stock.
The current consensus rating on Cidara Therapeutics (NASDAQ:CDTX) is Buy (Score: 3.20) with a consensus target price of $12.85 per share, a potential 62.66% upside.
Some recent analyst ratings include
- 7/28/2017-WBB Securities was Downgraded by analysts at WBB Securities from a “Strong-Buy” rating to a “” rating.
- 6/26/2017-Cantor Fitzgerald initiated coverage with a Overweight rating.
- 5/16/2017-Wedbush Reiterated Rating of Outperform.
- 4/29/2017-BTIG Research Reiterated Rating of Buy.
- 4/20/2017-Raymond James Financial, Inc. initiated coverage with a Strong-Buy rating.
- 4/17/2017-HC Wainwright Reiterated Rating of Buy .
- 4/12/2017-Ladenburg Thalmann Financial Services initiated coverage with a Buy rating.
Recent Insider Trading Activity For Cidara Therapeutics (NASDAQ:CDTX)
Cidara Therapeutics (NASDAQ:CDTX) has insider ownership of 18.90% and institutional ownership of 68.26%.
- On 6/7/2017 Taylor Sandison, Insider, bought 20,000 with an average share price of $5.90 per share and the total transaction amounting to $118,000.00. View SEC Filing
- On 6/5/2017 Jeffrey Stein, CEO, bought 15,000 with an average share price of $5.95 per share and the total transaction amounting to $89,250.00. View SEC Filing
- On 3/31/2017 Jeffrey Stein, CEO, bought 12,900 with an average share price of $7.75 per share and the total transaction amounting to $99,975.00. View SEC Filing
- On 3/31/2017 Kevin Forrest, Insider, bought 12,500 with an average share price of $7.75 per share and the total transaction amounting to $96,875.00. View SEC Filing
- On 5/20/2016 Jeffrey Stein, CEO, bought 4,310 with an average share price of $11.51 per share and the total transaction amounting to $49,608.10. View SEC Filing
- On 5/20/2016 Kevin Forrest, CFO, bought 4,356 with an average share price of $11.53 per share and the total transaction amounting to $50,224.68. View SEC Filing
- On 11/25/2015 Jeffrey Stein, CEO, bought 6,700 with an average share price of $15.09 per share and the total transaction amounting to $101,103.00. View SEC Filing
Recent Trading Activity for Cidara Therapeutics (NASDAQ:CDTX)
Shares of Cidara Therapeutics closed the previous trading session at 7.38 down -0.53 -6.65% with 162,151 shares trading hands.